Rox Medical, a US-based provider of treatment for hypertension and chronic obstructive pulmonary diseases, has enrolled the first UK patients in a controlled, randomised study of its Rox FLOW catheter procedure for the treatment of resistant hypertension.
Under the minimally invasive procedure, which is being undertaken at Eastbourne General Hospital, East Sussex, UK, a small coupler will be placed between the artery and vein in the upper leg to reduce peripheral vascular resistance and offer long-term reduction in hypertension.
The procedure also involves vascular structures away from vital organs like the kidneys, and does not require heavy pain medications common to renal ablation techniques, according to the company.
Eastbourne General Hospital Dr Stephan Furniss said the procedure was painless and the patient showed significant improvement in blood pressure after the procedure.
"This could be a very important new device treatment option for resistant hypertension patients," Furniss said.
"We are anxious to enroll additional patients into this exciting trial."
ROX Medical CEO Rodney Brenneman said; "We are honored and excited to have the highly respected team of cardiologists at Eastbourne involved in the CONTROL-HTN study."
The catheter procedure for hypertension is not approved for use in the US.
ROX Medical also recently enrolled the first two Irish patients to evaluate the treatment of resistant hypertension at Beaumont Hospital and Connolly Hospital.